Sort   by:  
 Page size 
ProteomicsProteomics assisted studies of the host nuclear proteome identifies candidate regulators of immunity modified during Phytophthora capsici-tomato interactions
In this study we have combined nuclei enrichment with quantitative proteomics to study tomato nuclear proteome dynamics during early infection with the devastating broad host-range oomycete pathogen Phytophthora capsici. Using this method we have identified hundreds of host nuclear proteins that sho...
ORGANISM(S): Solanum lycopersicum 
2017-04-18 | PXD003260 | Pride
Tomato Nucleus Immunity Phytophthora Quantitative proteomics Plant-microbe interactions 
UnknownOutcome of Second Primary Malignancies Developing in Multiple Myeloma Patients
Not available
S-EPMC10487060 | biostudies-literature
UnknownGMP Manufacturing and IND-Enabling Studies of a Recombinant Hyperimmune Globulin Targeting SARS-CoV-2.
Not available
S-EPMC9320065 | biostudies-literature
UnknownGlobal human footprint on the linkage between biodiversity and ecosystem functioning in reef fishes.
Not available
S-EPMC3071368 | biostudies-literature
UnknownTime-to-event analysis mitigates the impact of symptomatic therapy on therapeutic benefit in Parkinson's disease trials.
Not available
S-EPMC12214479 | biostudies-literature
UnknownExploratory digital outcome measures of motor sign progression in Parkinson's disease patients treated with prasinezumab.
Not available
S-EPMC12170883 | biostudies-literature
UnknownHoehn and Yahr Stage and Striatal Dat-SPECT Uptake Are Predictors of Parkinson's Disease Motor Progression.
Not available
S-EPMC8711238 | biostudies-literature
UnknownChanges in Body Mass Index in Children and Adolescents Living With Human Immunodeficiency Virus in Europe and Thailand Starting Dolutegravir.
Not available
S-EPMC12712701 | biostudies-literature
UnknownA Phase II Study to Evaluate the Safety and Efficacy of Prasinezumab in Early Parkinson's Disease (PASADENA): Rationale, Design, and Baseline Data.
Not available
S-EPMC8518716 | biostudies-literature
UnknownCharacterization of the clinical and immunologic phenotype and management of 157 individuals with 56 distinct heterozygous NFKB1 mutations.
Not available
S-EPMC8246418 | biostudies-literature
Sort   by:  
 Page size